Intravenous immunoglobulin

Overview
Intravenous immunoglobulin (IVIG) is a blood product administered intravenously. It contains the pooled IgG immunoglobulins (antibodies extracted from the plasma of over a thousand blood donors). IVIG's effects last between 2 weeks and 3 months. It is mainly used as treatment in three major categories:
 * Immune deficiencies - Immune deficiencies such as X-linked agammaglobulinemia, hypogammaglobulinemia (primary immune deficiencies), and acquired compromised immunity conditions ([secondary immune deficiencies), featuring low antibody levels.
 * Inflammatory and autoimmune diseases.
 * Acute infections.
 * In 2004 the FDA approved the Cedars-Sinai IVIG Protocol which has been 90-95% successful in removing antibodies from the blood of kidney transplant recipients so that they can accept a living donor kidney from any healthy donor no matter blood type (ABO incompatible) or tissue match.

Mechanism of action
IVIG is given as a plasma protein replacement therapy (IgG) for immune deficient patients which have decreased or abolished antibody production capabilities. IVIG is administered to maintain adequate antibodies levels to prevent infections and confers a passive immunity. Treatment is given every 3-4 weeks.

The precise mechanism by which IVIG suppresses harmful inflammation is believed to be through the Fc receptor.

Additionally, the donor antibody may bind directly with the abnormal host antibody, stimulating its removal. Alternatively, the massive quantity of antibody may stimulate the host's complement system, leading to enhanced removal of all antibodies, including the harmful ones. IVIG also blocks the antibody receptors on immune cells (macrophages), leading to decreased damage by these cells, or regulation of macrophage phagocytosis.

IVIG may also regulate the immune response by reacting with a number of membrane receptors on T cells, B cells, and monocytes that are pertinent to autoreactivity and induction of tolerance to self.

A recent report stated that IVIG application to activated T cells leads to their decreased ability to engage microglia. As a result of IVIg treatment of T cells, the findings showed reduced levels of tumor necrosis factor-alpha and interleukin-10 in T cell-microglia co-culture. The results add to the understanding of how IVIG may affect inflammation of the central nervous system in autoimmune inflammatory diseases.

IVIG is useful in some acute infection cases such as in Kawasaki's Disease and pediatric HIV infection.

IVIG notes

 * IVIG is an infusion of IgG antibodies only. Therefore, peripherial tissues that are defended mainly by IgA antibodies, such as the eyes, lungs, gut and urinary tract are not fully protected by the IVIG treatment.
 * XLA patients are immune to the most virulent adverse effect, anaphylactic shock, as they do not have the antibodies to react against the treatment. Anaphylactic shock has a higher chance to occur in IgA deficient patients which do have other antibody types.
 * In case of recurring side effects, it is recommended to slow the pace of the IVIG administration and to reduce the dosage. It is also advisable to change IVIG brand, as some people react against to a specific brand.
 * If the patient is diabetic, he should take into consideration the medium in which the antibodies are solubilized in the IVIG treatment, as some brand solubilize antibodies with high concentrated sugars (such as sucrose and maltose).
 * FDA guidelines for IVIG state the product should be:
 * Prepared out of at least 1,000 different human donors.
 * All four IgG subgroups (1-4) should be present.
 * The IgG should maintain biological activity and lifetime of at least 21 days.
 * Does not contain samples which are HIV, hepatitis B, hepatitis C positive.
 * Screened and treated in a manner that destroys viruses.
 * IVIG is also considered a modulator of the immune system and was shown to be beneficial in treating numerous autoimmune diseases such as rheumatoid arthritis (RA), lupus erythematosus (SLE), multiple sclerosis (MS), myasthenia gravis, pemphigus, polymyositis (PM), dermatomyositis (DM), Wegener's granulomatosis (WG), Churg-Strauss syndrome, chronic inflammatory demyelinating polyneuropathy and more.
 * IVIG can be given to pregnant women.
 * IVIG is also used as a treatment for unexplained recurring miscarriages. The effectiveness of the therapy is controversial.

Uses of IVIG
Dosage of IVIG is dependent on indication.

For primary immune dysfunction 100 to 400 mg/kg of body weight every 3 to 4 weeks is implemented.

For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three to six months over a five day course once a month. Then maintenance therapy of 100 to 400 mg/kg of body weight every 3 to 4 weeks follows.

FDA-approved indications

 * Allogeneic bone marrow transplant
 * Chronic lymphocytic leukemia
 * Idiopathic thrombocytopenic purpura
 * Pediatric HIV
 * Primary immunodeficiencies
 * Kawasaki disease
 * Kidney transplant with a high antibody recipient or with an ABO incompatible donor

Off-label Uses

 * Chronic fatigue syndrome
 * Chronic inflammatory demyelinating polyneuropathy (CIDP)
 * Clostridium difficile colitis
 * Dermatomyositis and polymyositis
 * Fetomaternal alloimmune thrombocytopenia
 * Graves' ophthalmopathy
 * Guillain-Barré syndrome
 * Kawasaki disease
 * Inclusion body myositis
 * Lambert-Eaton syndrome
 * Lupus erythematosus
 * Multifocal motor neuropathy
 * Multiple sclerosis
 * Myasthenia gravis
 * Pemphigus
 * Post-transfusion purpura
 * Renal transplant rejection
 * Stiff person syndrome
 * Toxic epidermal necrolysis
 * In chronic lymphocytic leukemia and multiple myeloma, as well as various rare deficiencies of immunoglobulin synthesis (e.g. X-linked agammaglobulinemia, hypogammaglobulinemia), IVIG is administered to maintain adequate immunoglobulin levels to prevent infections.

Complications and side effects
Complications of IVIG therapy include


 * headache
 * dermatitis - usually peeling of the skin of the palms and soles
 * infection (such as HIV or viral hepatitis) by contaminated blood product; there is also an as yet unknown risk of contracting variant CJD (vCJD).
 * pulmonary edema from fluid overload, due to the high colloid oncotic pressure of IVIG
 * allergic/anaphylactic reactions
 * damage such as hepatitis caused directly by antibodies contained in the pooled IVIG
 * acute renal failure
 * venous thrombosis
 * aseptic meningitis